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Abstract
An inflammatory microenvironment may cause organ degenerative diseases and malignant tumors.
However, the precise mechanisms of inflammation-induced diseases are not fully understood. Here we
show that the proinflammatory cytokines interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α)
synergistically impair self-renewal and differentiation of mesenchymal stem cells (MSCs) via nuclear
factor κB (NFκB)–mediated activation of Mothers against decapentaplegic homolog 7 (SMAD7) in
ovariectomized (OVX) mice. More interestingly, a long-term elevated levels of IFN-γ and TNF-α result in
significantly increased susceptibility to malignant transformation in MSCs through NFκB–mediated
upregulation of the oncogenes c-Fos and c-Myc. Depletion of either IFN-γ or TNF-α in OVX mice abolishes
MSC impairment and the tendency toward malignant transformation with no NFκB–mediated oncogene
activation. Systemic administration of aspirin, which significantly reduces the levels of IFN-γ and TNF-α,
results in blockage of MSC deficiency and tumorigenesis by inhibition of NF-κB/SMAD7 and NFκB/c-FOS
and c-MYC pathways in OVX mice. In summary, this study reveals that inflammation factors, such as IFNγ and TNF-α, synergistically induce MSC deficiency via NFκB/SMAD7 signaling and tumorigenesis via
NFκB–mediated oncogene activation.
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Abstract
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An inflammatory microenvironment may cause organ degenerative diseases and malignant
tumors. However, the precise mechanisms of inflammation-induced diseases are not fully
understood. Here we show that the proinflammatory cytokines interferon ! (IFN-!) and tumor
necrosis factor " (TNF-") synergistically impair self-renewal and differentiation of mesenchymal
stem cells (MSCs) via nuclear factor #B (NF#B)–mediated activation of Mothers against
decapentaplegic homolog 7 (SMAD7) in ovariectomized (OVX) mice. More interestingly, a longterm elevated levels of IFN-! and TNF-" result in significantly increased susceptibility to
malignant transformation in MSCs through NF#B–mediated upregulation of the oncogenes c-Fos
and c-Myc. Depletion of either IFN-! or TNF-" in OVX mice abolishes MSC impairment and the
tendency toward malignant transformation with no NF#B–mediated oncogene activation.
Systemic administration of aspirin, which significantly reduces the levels of IFN-! and TNF-",
results in blockage of MSC deficiency and tumorigenesis by inhibition of NF-#B/SMAD7 and
NF#B/c-FOS and c-MYC pathways in OVX mice. In summary, this study reveals that
inflammation factors, such as IFN-! and TNF-", synergistically induce MSC deficiency via
NF#B/SMAD7 signaling and tumorigenesis via NF#B–mediated oncogene activation.

Keywords
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Mesenchymal stem cells; Stem cell-microenvironment interactions; Differentiation; Cancer;
Cytokines

INTRODUCTION
Degenerative diseases, such as osteoporosis, usually show elevated inflammatory activity [1,
2]. Postmenopausal osteoporosis is the most common form of osteoporosis, in which
estrogen deficiency-induced T cell activation promotes osteoclastogenesis to reduce bone
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mineral density (BMD) [3–5]. Although antiresorptive therapies have been utilized in
clinical treatment, concerns have been raised by the emergence of side effects, such as
bisphosphonate-related osteonecrosis of the jaw (BRONJ) [6, 7]. Thus, it is critical to further
understand the underlying mechanisms of osteoporosis and develop novel therapeutic
strategies accordingly.
Mesenchymal stem cells (MSCs) are a population of stromal progenitor cells with selfrenewal and multipotent differentiation capabilities, possessing the potential to replace
damaged and diseased tissues [8, 9]. Accumulating evidence shows that deficiency in MSC/
osteoblast lineage consistently contributes to bone degenerative phenotypes in osteoporosis
in both mice and humans [2, 10–13]. However, it remains unclear how MSCs are impaired
in these immune disorder–associated diseases. If left untreated, degenerative diseases may
become a risk factor for cancer occurrence [14, 15], in which chronic infections may play an
important role [16]. Moreover, anti-inflammatory treatments show effectiveness in reducing
the risk of cancer metastasis [17]. It was speculated that either osteosarcoma or Ewing's
sarcoma may directly originate from spontaneous mutation of bone marrow-derived MSCs
[18–21]. Therefore, it is possible that a long-term inflammatory environment may eventually
induce MSC tumorigenesis.
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It has been proved that MSCs closely interact with the host immune system. MSCs are able
to inhibit proinflammatory cytokines by targeting several subsets of immune cells, including
T cells, B cells, dendritic cells and natural killer cells [22–24], and such immunoregulatory
property of MSCs provides the foundation for clinical applications in treating several
autoimmune diseases [2, 25]. Conversely, immune components target MSCs. For example,
activated T-cells can induce bone marrow MSC apoptosis via the TNF receptor superfamily
member 6 (FAS)/FASL and CD40/CD40L pathways, respectively [10, 26]. Lymphocytes
can impair survival of implanted MSCs by secreting the proinflammatory cytokines IFN-!
and TNF-", thereby negatively affecting MSC-mediated tissue regeneration [27, 28].
However, it remains unknown whether specific inflammatory factors, such as IFN-! and
TNF-", affect MSC properties in an immune disorder-associated model, including OVXinduced osteoporotic mice. Among many inflammatory cytokines, IFN-! and TNF-" have
been proved to play crucial roles in estrogen–deficient osteoporosis [29, 30]. Previous
studies have shown that OVX enhances production of TNF-" by T cells, which in turn,
augments macrophage colony-stimulating factor (M-CSF)– and receptor activator of NF-#B
ligand (RANKL)–induced osteoclastogenesis [29]. Furthermore, it has been demonstrated
that OVX upregulates IFN-!–induced class II transactivator, resulting in enhanced T cell
activation and prolonged lifespan of activated T cells [30].
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Mothers against decapentaplegic homolog 7, or SMAD7, is an important inhibitory factor of
the TGF$/SMAD pathway, which is one of important signaling pathways regulating
osteogenic differentiation. The relationship between SMAD7 and NF-#B is not clear.
Although it was reported that SMAD7 inhibits nuclear translocation and transcriptional
activity of the cell survival factor NF-#B [31, 32], other studies demonstrated that
proinflammatory cytokines, such as interleukin-1$ (IL-1$) and TNF-", upregulated SMAD7
through the activation of the NF-#B pathway in fibroblasts and chondrocytes [33, 34].
Therefore, IFN-! and TNF-" may upregulate SMAD7 via the activation of the NF-#B
pathway, thereby inducing the deficiency of osteogenic differentiation of MSCs. In this
study, we determine that IFN-! and TNF-", as critical inflammatory factors, synergistically
induce MSC deficiency via NF#B/SMAD7 signaling, whereas their long-term effect can
result in the induction of MSC tumorigenesis by NF#B–mediated oncogene activation.
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MATERIALS AND METHODS
Animals
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Female C3H/HeJ, C57BL/6, TNF-" knockout mice (B6;129S-Tnftm1Gkl/J) and IFN-!
knockout mice (B6.129S7-Ifngtm1Ts/J) were purchased from Jackson Lab (Bar Harbor, ME).
Generation of ovariectomized (OVX) mice was performed as described previously [35] and
age–matched mice receiving sham operation served as control. Female
immunocompromised mice (Beige nude/nude XIDIII) were purchased from Harlan
(Indianapolis, IN). These animal experiments were performed under institutionally approved
protocols for the use of animal research (University of Southern California # 10941, 11141
and 11327).
Antibodies
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Anti-mouse TNF-", SMAD7, alkaline phosphatase (ALP), TNF receptor-1 (TNFR1),
TNFR2, IFN-! receptor " (IFNGR"), Vimentin (VIM), pan-Cytokeratin (pan-CK),
proliferating cell nuclear antigen (PCNA), c-FOS and c-MYC antibodies were purchased
from Santa Cruz Biotech (Santa Cruz, CA); IFN-! antibody was purchased from Abbiotec
(San Diego, CA); phosphorylated nuclear factor #B (p-NF#B), NF#Bp65, p-NF#Bp50,
NF#Bp50, phosphorylated nuclear factor # B inhibitor (p-I#B), I#B", p-SMAD1, SMAD1,
runt-related transcription factor 2 (RUNX2) and Signal Transducers and Activators of
Transcription factor 1 (STAT-1) were purchased from Cell Signaling (Danvers, MA). Anti$-Actin antibody was purchased from Sigma-Aldrich (St. Louis, MO).
Measurement of TNF-" and IFN-! in blood serum, bone marrow, derma and fat
Peripheral blood was collected from retro-orbital venous plexus, and IFN-! and TNF-"
ELISA (BioLegend, San Diego, CA) was performed to detect in blood serum according to
their manufactures' instructions. Total protein from bone marrow, derma and subcutaneous
fat was extracted using M-PER mammalian protein extraction reagent (Thermo, Rockford,
IL), and IFN-! and TNF-" were measured by ELISA, respectively.
Isolation of mouse MSCs
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For isolation of bone marrow MSCs, bone marrow cells were flushed out from bone cavity
of femurs and tibias of mice with 2% heat-inactivated fetal bovine serum (FBS; EquitechBio, Kerrville, TX) in PBS. For isolation of dermal MSCs and subcutaneous fat MSCs,
dermis and subcutaneous fat were carefully separated from the full skin under a dissecting
microscope, cut into small pieces and digested with 1.5 mg/mL collagenase type I
(Worthington, Lakewood, NJ) and Dispase (Roche, Indianapolis, IN) in PBS 2 mg/mL for 1
hour at 37 °C to release the individual cells. A single-cell suspension of all nucleated cells
was obtained by passing all bone marrow cells through a 70-%m cell strainer (BD
Bioscience, San Jose, CA), respectively. All the single cells were seeded into 100-mm
culture dishes (Corning, Corning, NY) and initially incubated for 48 h at 37 °C and 5% CO2.
To eliminate the nonadherent cells, the cultures were washed with PBS twice on the second
day. The attached cells were cultured for 16 d with alpha minimum essential medium ("MEM, Invitrogen, Grand Island, NY) supplemented with 20% FBS, 2 mM L-glutamine
(Invitrogen), 55 %M 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 %g/ml
streptomycin (Invitrogen). To confirm mesenchymal stem cell character, flow cytometric
analysis was used to show that these MSCs were positive for CD73, CD90, Sca-1 and
SSEA-4 and negative for CD11b, CD31, CD34 and CD45.
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Population-doubling assay
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Population doublings (PD) for each passage was determined by using the formula
PD&log2[Nc/No], where No is the original cell population and Nc is the number of cells at
confluence, and by adding the PD from each passage together to obtain the PD values. The
PD assay for mouse MSCs began with passage 1.
Osteogenic differentiation of MSCs
For osteogenic induction in vitro, mouse MSCs were seeded on 35-mm dishes (Corning) and
cultured in the growth medium until the cells reached confluence. To induce osteogenic
differentiation, the medium was changed to an osteogenic medium consisting of L-ascorbic
acid phosphate and $-glycerophosphate. Two weeks after osteogenic induction, total protein
was extracted and analyzed for osteogenic markers by Western blot. After 4–6 weeks,
calcium deposits formed by osteoblasts on the dishes were detected by staining with 2%
Alizarin Red (Sigma-Aldrich).
Histological and histomorphometric analysis
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Femurs and skins were fixed with 4% paraformaldehyde, followed by decalcification with
10% EDTA (pH 8.0) for femurs, and embedded in paraffin. For histological and
histomorphometric analysis, sections were deparaffinized and stained with H&E, followed
by trabecular percentage and derma thickness calculation using ImageJ software.
Immunohistochemistry staining
For detection of TNF-", IFN-!, VIM, pan-CK, PCNA, p-NF#Bp65, c-FOS and c-MYC, the
sections were blocked with serum matched to secondary antibodies, incubated with the first
antibodies for 30min at room temperature, and stained using VECTASTAIN Elite ABC Kit
(Vector, Burlingame, CA) and DAB Kit (Invitrogen), according to the manufacturers'
instructions.
Administration of IFN-! and TNF-" neutralizing antibodies in OVX mice
To chronically deplete IFN-! and TNF-", at 1 day before OVX, 12-week-old female C3H
mice were injected intraperitoneally (IP) with 250 %g of IFN-! and TNF-" neutralizing
antibodies (BioLegend) in 0.5 ml sterile saline every 3 days until 21 days post-OVX,
respectively. In control groups, 250 %g isotype control antibodies in 0.5 ml sterile saline
were identically administered.
Administration of IFN-! and TNF-" in nude mice
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To mimic IFN-!- and TNF-"-induced MSC deficiency an in vivo model, 8-week-old
female nude mice were injected with 4 %g recombinant mouse IFN-! (BioLegend) and 1 %g
recombinant mouse TNF-" (BioLegend), either alone or in combination, in 0.2 ml sterile
saline via tail vein every 3 days for 21 days, respectively.
Inhibition of osteogenic differentiation by IFN-! and TNF-" treatment
Half a million MSCs were seeded onto each 6-well culture dish (Corning) with or without
treatment using I#B kinase " (IKK"), SMAD7, TNFR1 or IFNGR" siRNA (Santa Cruz)
according to the manufacturer's instruction. IFN-! and TNF-", either alone or
incombination, were used to treat the MSCs with normal growth media or osteogenic media
for 14 days. Total protein was extracted for detection of NF#B pathway and osteogenic
markers using Western blot. For some experiments, the culture plates were stained with 2%
toluidine blue O and 2% paraformaldehyde to evaluate cell survival.
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Western blot analysis
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Total protein was extracted using M-PER mammalian protein extraction reagent (Thermo).
Nuclear protein was obtained using NE-PER nuclear and cytoplasmic extraction reagent
(Thermo). Protein was applied and separated on 4–12% NuPAGE gel (Invitrogen) and
transferred to ImmobilonTM-P membranes (EMD Millipore, Billerica, MA). After blocking
with 5% non-fat dry milk for 1 hour, the membranes were incubated with the primary
antibodies (1:200–1000 dilution) at 4 °C overnight. Horseradish peroxidase-conjugated IgG
(Santa Cruz) was used to treat the membranes for 1 hour and subsequently treated with a
chemiluminescent substrate (Thermo). The bands were detected on BIOMAX MR films
(Kodak). Each membrane was also stripped using a stripping buffer (Thermo) and re-probed
with anti-$-Actin to determine the loading amount.
Sarcomagenesis of BMMSCs in MCA-treated Mice
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In order to determine the susceptibility to tumorigenesis of BMMSCs in vivo, we locally
applied 3-methycholanthrene (MCA) to the bone marrow of tibias as a carcinogen to induce
osteosarcoma according to the method described in previous studies with modifications [36,
37]. One month after OVX or sham operation, a small hole was created in the metaphysis of
right tibia using a dental bur after anesthesia, and a single dose of 0.5 mg MCA in 10 ul of
dimethyl sulfoxide (DMSO) was injected into the bone marrow of tibia, followed by sealing
using bone wax. Control mice received identical procedures except that DMSO without
MCA was implanted into tibias. MCA-treated mice were closely observed for tumor
occurrence for up to 4 months. MCA-treated tibias were harvested, demineralized with 10%
EDTA, and embedded for hematoxylin and eosin (H&E), trichrome staining and
immunostainings for VIM, pan-CK and PCNA.
MSC spontaneous malignant transformation assay
To evaluate the effects of inflammatory microenvironment to MSC malignant
transformation in vitro, we treated mouse BMMSCs with long-term IFN-! (50 ng/ml) and
TNF-" (5 ng/ml), with or without treatment of NF#B inhibitor BAY 11-7082 (1 %M,
Sigma-Aldrich), and continuously passaged to gradually acquire unlimited population
doublings as previously described [18]. Giemsa staining was performed to monitor the cell
shape.
Transplantation and injection of BMMSCs
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To assess tumorigenesis and migration potential, 2×106 and 1×106 of BMMSCs were
injected into 8-week-old nude mice subcutaneously and intravenously through tail vein,
respectively. Transplants and lungs were harvested 8 weeks after transplantation, and the
paraffin-embedded sections were stained with H&E, Trichrome, or incubated with VIM,
pan-CK and PCNA antibodies (Santa Cruz) for immunohistochemistry analysis.
Semiquantitative real-time polymerase chain reaction (RT-PCR)
Total RNA was isolated from the cultures using SV total RNA isolation kit (Promega,
Madison, WI) following the manufacturer's protocols. The cDNA was synthesized from 100
ng of total RNA using Superscript III (Invitrogen). PCR was performed on a CFX 96 realtime PCR thermocycler (BioRad, Hercules, CA) using gene-specific primers and
Cybergreen supermix (BioRad, Hercules, CA). Primer pairs are as follows: mouse c-Fos,
forward primer (AAACCGCATGGAGTGTGTTGTTCC) and reverse primer
(TCAGACCACCTCGACAATGCATGA); mouse c-Myc, forward primer
(GCCACGTCTCCACACATCAG) and reverse primer
(TCTTGGCAGCAGGATAGTCCTT). The conditions for amplification were as follows: 94
°C for 5 min, followed by 40 cycles of 94 °C for 20 s; 60 °C for 20 s; and 72 °C for 25 s.
Stem Cells. Author manuscript; available in PMC 2014 July 01.
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Data from the real-time PCR reactions were analyzed using CFX Manager™ Software,
Version 2 (Bio-Rad Laboratories). Relative changes in mRNA expression were analyzed
using the 2-''Ct method, with Gapdh serving as an internal reference to correct for
differences in RNA extraction or reverse transcription efficiencies. These standardized data
were used to calculate fold-differences in gene expression. All real-time PCR amplifications
were performed in triplicate.
Aspirin administration in OVX mice
To determine the effects of aspirin to prevent MSC tumorigenesis and MSC deficiency in
vivo, mice were fed with aspirin (1 mg/ml, Sigma-Aldrich) dissolved in water or placebo for
2 months in OVX mice and 4 months in MCA-treated OVX mice. BMMSCs and DMSCs
were harvested for PD and osteogenic differentiation analysis.
Statistics
SPSS 13.0 was used to perform statistical analysis. Significance was assessed by
independent two-tailed Student's t-test or analysis of variance (ANOVA). The P values less
than 0.05 were considered significant.

RESULTS
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Elevated levels of IFN-! and TNF-" synergistically impair MSCs in OVX mice

NIH-PA Author Manuscript

Of many immune disorder–associated degenerative diseases, postmenopausal osteoporosis is
an important example. It features overactivation of proinflammatory cytokine-producing T
cells and decreased osteogenic differentiation capabilities in bone marrow MSCs
(BMMSCs), resulting in reduced bone mineral density (BMD) [2–5, 10]. IFN-! and TNF-"
have been proved to play crucial roles in estrogen–deficient osteoporosis [29, 30]. Blockage
of either IFN-! or TNF-" can abolish OVX-induced osteoporotic phenotype [3, 5].
Moreover, OVX enhances T cell activation and prolonged lifespan of active T cells through
IFN-!-induced class II transactivator [30]. Our recent study also showed that IFN-! and
TNF-" synergistically impaired implanted MSCs in vivo [28]. Based on these observations,
we asked whether IFN-! and TNF-" would affect MSC properties in OVX-induced
osteoporotic mice. We hypothesized that IFN-! and TNF-", as two key representatives in
the inflammatory microenvironment, might synergistically play an important role in
inducing MSC deficiency in OVX-induced osteoporotic mice. Concentrations of both IFN-!
and TNF-" in serum, bone marrow and derma, but not in subcutaneous fat, were markedly
increased in OVX mice when compared with sham-operated mice by ELISA and
immunohistochemical staining analysis (Fig. 1A; Supporting Information Fig. S1).
BMMSCs derived from OVX mice showed markedly decreased population doublings when
compared to sham mouse-derived BMMSCs, indicating that BMMSC self-renewal
capability was impaired in OVX mice (Fig. 1B). Importantly, osteogenic differentiation of
BMMSCs was also impaired in OVX mice, as indicated by Alizarin red staining to show
markedly decreased mineralized nodule formation after induction of osteogenic media (Fig.
1C). Because derma and subcutaneous fat, as neighboring tissues, showed different
alteration in the levels of IFN-! and TNF-" following OVX procedure (Fig. 1A), we
speculate that OVX may affect derma and subcutaneous fat MSCs differently from bone
marrow MSCs. Although OCT-4 is not a specific marker for MSCs, it has been proved to be
an important marker to indicate that MSCs possess self-renewal capacity and can retain their
undifferentiated status [38]. Therefore, we used OCT-4 as a marker of functional stem cell
assurance for MSCs. We found that the derma, but not the fat, from OVX mice harbored
markedly less OCT-4–positive MSCs (Fig. 1D), contributing to a markedly decreased
collagen deposition in the derma as shown by Trichrome staining, when compared with
sham-operated mice (Fig. 1E). To further confirm decreased MSC number in OVX mice, we
Stem Cells. Author manuscript; available in PMC 2014 July 01.
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performed histoimmunostaining to show markedly reduced number of dermal MSCs, which
express the MSC markers CD105, CD44 and CD73 in OVX mice (Supporting Information
Fig. S2). Moreover, OVX-derived dermal MSCs (DMSCs), but not fat MSCs (FMSCs),
showed markedly decreased population doublings (Fig. 1F) and osteogenic differentiation
(Fig. 1G), which served as a representative to determine the differentiation capabilities of
MSCs in the experiments thereafter. Consequently, OVX mice showed markedly
deteriorated trabecular bone structures and reduced dermal thickness when compared with
sham-operated mice (Supporting Information Fig. S3 A, S3 B).
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We next asked whether elevated levels of IFN-! and TNF-" would synergistically cause
MSC deficiency. To clarify this, we first systemically administered either IFN-! or TNF-"
neutralizing antibody to OVX mice to test whether depletion of IFN-! or TNF-" could
prevent OVX-induced MSC deficiency. Indeed, administration of IFN-! neutralizing
antibody was able to markedly reduce IFN-! level in the serum of OVX mice, without
affecting TNF-" level; similarly, administration of TNF-" neutralizing antibody could
markedly reduce the serum TNF-" level in OVX mice, without changing IFN-! level (data
not shown). Interestingly, histological analysis showed that either IFN-! or TNF-"
neutralizing antibody was able to markedly inhibit bone loss in OVX mice (Fig. 2A). MSC
characterization showed that either IFN-! or TNF-" neutralizing antibody treatment in vivo
markedly improved population doublings and osteogenic differentiation in OVX-derived
BMMSCs (Fig. 2B). Also, either IFN-! or TNF-" neutralizing antibody was able to prevent
derma atrophy in OVX mice (Fig. 2C) and improve population doublings and differentiation
capabilities in OVX-derived DMSCs (Fig. 2D). In order to further dissect whether IFN-!
and TNF-" synergistically cause MSC deficiency in OVX mice, we confirmed that OVX
was not able to induce BMD loss in either IFN-! knockout or TNF-" knockout mice (Fig.
2E, 2F). Importantly, population doublings and differentiation capabilities were not
decreased in BMMSCs or DMSCs in IFN-! knockout or TNF-" knockout mice after OVX
(Fig. 2E, 2F). To further confirm the synergistic effect of IFN-! and TNF-" in vivo, we
systemically infused IFN-! and TNF-", either alone or in combination, to
immunocompromised mice via tail vein. Interestingly, infusion of IFN-! and TNF-" in
combination, but not separately, caused a dramatic reduction in population doublings and
differentiation capabilities of both BMMSCs and DMSCs (Fig. 3A–3D), resulting in both
osteopenia phenotype and dermal atrophy with poor collagen deposition as shown by
Trichrome staining (Fig. 3E–3G; Supporting Information Fig. S4 A, S4 B). Furthermore,
when IFN-! and TNF-", either alone or in combination, were subcutaneously transplanted
with hydrogel as a controlled release system, DMSC population doublings and
differentiation capabilities were reduced by IFN-! and TNF-" in combination, but not
separately (Supporting Information Fig. S5 A, S5 B), thereby causing derma atrophy
(Supporting Information Fig. S5 C). These in vivo data suggest that elevated levels of IFN-!
and TNF-" synergistically, but not independently, cause MSC deficiency.
IFN-! and TNF-" synergistically induce NF#B/SMAD7 pathway activation, causing
differentiation deficiency in MSCs
In order to examine the mechanism by which IFN-! and TNF-" synergistically induce
impairment of MSCs, we demonstrated that BMMSCs and DMSCs derived from OVX mice
showed the upregulation of p-NF#B, p-I#B and inhibitory SMAD7, but the downregulation
of osteogenic genes, including phosphorylated SMAD1 (p-SMAD1), RUNX2 and ALP (Fig.
4A; Supporting Information Fig. S6 A). To mimic in vivo microenvironment in OVX bone
marrow, we treated BMMSCs with IFN-! and TNF-" in different concentrations, either
alone or in combination, and found that TNF-"-induced NF#Bp65 activation in a dosedependent manner with a maximal activation at concentrations of 5 and 20 ng/ml
(Supporting Information Fig. S6 B), whereas the combination of IFN-! (50 ng/ml) and
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TNF-" (5 ng/ml) induced more significant upregulation of NF#Bp65 signaling (Fig. 4B).
Interestingly, IFN-! and TNF-" in combination, but not separately, caused a significant
reduction of mineralized nodule formation in BMMSCs (Fig. 4C) and DMSCs cultured in
osteogenic media (Supporting Information Fig. S6 C, S6 D), without dramatically affecting
MSC survival (Fig. 4E). Furthermore, Western blot showed that IFN-!/TNF-"–induced
NF#B activation upregulated inhibitory SMAD7, but downregulated osteogenic genes,
including p-SMAD1, RUNX2, and ALP (Fig. 4F). When NF#B expression was knocked
down by IKK" siRNA, IFN-!/TNF-"–induced upregulation of SMAD7 and
downregulation of p-SMAD1, RUNX2, and ALP were abolished, leading to the rescue of
IFN-!/TNF-"–induced reduction of mineralized nodule formation in BMMSCs (Fig. 4G,
4H) and DMSCs (Supporting Information Fig. S6 E, S6 F). Under osteogenic induction,
IFN-! and TNF-" treatment in combination was able to dramatically upregulate IFN-!
receptor IFNGR" and TNF-" receptor TNFR1, but not TNFR2, when compared with IFN-!
and TNF-" treatment alone (Fig. 4D). Combination knockdown of IFNGR" and TNFR1
resulted in marked inhibition of IFN-!–/TNF-"–induced activation of NF#B pathway when
compared with knockdown of TNFR1 alone, suggesting that IFN-! activates TNF-"–
induced NF#B activation via IFNGR" (Supporting Information Fig. S7 A). Moreover, IFN!, either alone or in combination with TNF-", was able to markedly upregulate p-STAT-1
(Fig. 4D), whereas knockdown of STAT1 dramatically reduced the TNF-"–/IFN-!–induced
activation of NF#B pathway, suggesting that IFN-!/IFNGR" pathway enhances TNF-"–
triggered NF#B activation via STAT-1 activation (Supporting Information Fig. S7 B). We
confirmed the efficiency of IKK", IFNGR", TNFR1, STAT-1 and SMAD7 knockdown by
their specific siRNAs using Western blot analysis (Supporting Information Fig. S7 C, S7 D).
Additionally, knockdown of SMAD7 expression by siRNA assay resulted in rescuing TNF"–/IFN-!–induced reduction of mineralized nodule formation and downregulation of pSMAD1, RUNX2, and ALP in BMMSCs and DMSCs, without affecting p-I#B and p-NF#B
(Supporting Information Fig. S8 A–S8 D). These data suggest that SMAD7 acts as a
downstream target of NF#B signaling in TNF-"–/IFN-!–induced MSC osteogenic
deficiency.
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To further confirm the role of the NF#B pathway in TNF-"–/IFN-!–induced MSC
deficiency, we showed that NF#B inhibitor Bay 11-7082 treatment was able to rescue
osteogenic differentiation of OVX-derived BMMSCs by downregulating SMAD7 and
upregulating p-SMAD1, RUNX2, and ALP (Fig. 4I, 4J). To confirm the synergistic effects
of IFN-! and TNF-" that resulted in MSC deficiency in vivo, we demonstrated that OVX
failed to induce MSC NF#B activation in IFN-! and TNF-" knockout mice, respectively
(Fig. 4K, 4L). Moreover, either IFN-! or TNF-" neutralizing antibody treatment in vivo
was sufficient to downregulate NF#B pathway in BMMSCs to the level observed in the
sham-operated group (Fig. 4M). These in vivo results confirm that IFN-! and TNF-" work
synergistically to induce osteogenic deficiency in MSCs via NF#B pathway.
IFN-! and TNF-" increase the tendency toward MSC malignant transformation via NF#Bmediated upregulation of oncogenes c-Fos and c-Myc
Given the facts that degenerative diseases may be a risk factor for cancer occurrence [14]
and that NF#B activation may upregulate oncogenes c-Fos and c-Myc expression [39], we
next asked whether IFN-!–/TNF-"–induced NF#B activation could increase the tendency
toward MSC malignant transformation. When we extended the observation time to one-year
post-OVX, the aging OVX mice showed a markedly increased tumor incidence when
compared with aging sham-operated mice (Fig. 5A). Interestingly, ELISA showed that both
IFN-! and TNF-" concentration in serum remained markedly higher in OVX mice when
compared with sham-operated mice (Fig. 5B), suggesting that long-term overexposure of
MSCs to IFN-! and TNF-" may be associated with higher susceptibility to tumorigenesis in
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OVX mice. To confirm that such higher susceptibility of tumorigenesis involves MSCs, we
locally applied 3-methycholanthrene (MCA) as a carcinogen to induce osteosarcoma [36,
40], and found that the MCA-treated OVX mice showed a higher incidence of sarcoma with
earlier sarcoma occurrence in femurs when compared with sham-operated mice (Fig. 5C). In
tumors that occurred in MCA-treated OVX mice, but not sham-operated mice, histological
analysis showed the production of osteoid by atypical tumor cells with high mitotic activity
and abundant neovascularization, as well as osteogenic differentiation of the osteosarcomalike tumor cells, as indicated by Trichrome staining (Fig. 5D). Immunohistochemical costaining showed that CD73 was highly overlapped with VIM or PCNA (Fig. 5E), confirming
that the highly proliferating tumor cells mainly originated from mesenchymal cells, while
excluding the possibility of epithelial cell origin, as indicated by negative staining of panCK (Supporting Information Fig. S9 A). Furthermore, MCA-treated OVX mice showed a
markedly lower incidence of sarcoma with delayed sarcoma occurrence in IFN-! knockout
and TNF-" knockout mice, respectively, when compared with the sham-operated mice (Fig.
5F), suggesting again that IFN-! and TNF-" work synergistically to, in this case, induce
sarcomagenesis.
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These findings provided a strong rationale for further exploring the mechanisms by which
long-term IFN-!/TNF-" overexposure could induce MSC malignant transformation. To
achieve this, we used an established spontaneous malignant transformation assay [18] by
continuously passaging mouse BMMSCs to gradually acquire unlimited population
doublings. When treated with long-term IFN-!/TNF-" in vitro, the BMMSCs showed a
markedly quicker increase in population doublings after passage 10, whereas NF#B
inhibitor was able to delay such increase in population doublings (Fig. 6A). At passage 12,
IFN-!–/TNF-"–treated BMMSCs showed markedly smaller morphology with frequent
abnormal mitosis and the generation of sarcoma-like tumors upon s.c. inoculation, which,
when infused to nude mice via tail vein settled in the lungs with in situ tumorigenesis (Fig.
6B). In contrast, neither NF#B inhibitor-treated mice nor control mice showed any change
in cell morphology or generated any tumor upon s.c. inoculation or infusion into nude mice
(Fig. 6B). Immunohistochemical staining of the tumors derived from s.c. inoculation of IFN!–/TNF-"–treated BMMSCs revealed that the highly proliferating tumor cells originated
from mesenchymal cells, as indicated by high expressions of VIM and PCNA and negative
staining of pan-CK (Supporting Information Fig. S9 B).
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To further dissect the molecular mechanism of such IFN-!–/TNF-"–induced MSC
tumorigenesis, we demonstrated that the expression of c-MYC and c-FOS, was markedly
elevated in long-term IFN-!–/TNF-"–treated BMMSCs when compared with control
BMMSCs (Fig. 6C), but that knockdown of NF#B by IKK" siRNA assay was able to
abolish the elevation in c-MYC and c-FOS (Fig. 6C). To confirm this result in vivo, we
showed that c-Myc and c-Fos were markedly elevated in BMMSCs derived from aging
OVX mice when compared with sham-operated ones by using real-time PCR (Fig. 6D),
which was confirmed by Western blot and immunohistochemistry showing that c-MYC and
c-FOS expression was enhanced along with NF#B activation in aging OVX mice when
compared with sham-operated mice (Fig. 6E, Supporting Information Fig. S9 C).
Aspirin blocks OVX-induced MSC deficiency and tumorigenesis by inhibiting IFN-! and
TNF-"
Next, we investigated whether blocking the levels of IFN-! and TNF-" by pharmacological
approach could rescue MSC deficiency and tumorigenesis in vivo. Since aspirin has been
reported to inhibit the function of IFN-! and TNF-" [28, 41], we examined the effect of
systemic aspirin treatment in OVX mice which had undergone MCA injections in their
tibias. Interestingly, aspirin treatment dramatically reduced the concentrations of IFN-! and
TNF-" in both serum and bone marrow, resulting in a decreased and delayed osteosarcoma
Stem Cells. Author manuscript; available in PMC 2014 July 01.
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occurrence following MCA treatment (Fig. 7A, 7B), with marked inhibition of NF#B
activity in BMMSCs, as shown by Western blot analysis (Fig. 7C). The data suggest that
aspirin treatment may decrease the tendency toward MSC malignant transformation by
inhibiting IFN-!–/TNF-"–induced NFkB activation.
In order to determine the efficacy of aspirin administration to rescue IFN-!–/TNF-"–
induced MSC deficiency in organ degenerative diseases, we systemically applied aspirin to
OVX mice and found that aspirin could markedly improve BMD and rescue the deteriorated
trabecular bone structures and derma atrophy in OVX mice (Fig. 7D; Supporting
Information Fig. S10 A, S10 B), at least partly by reducing the concentrations of IFN-! and
TNF-" in serum, bone marrow and derma (Fig. 7E). Importantly, in vivo aspirin
administration was able to markedly improve population doublings and differentiation
capacities of both BMMSCs and DMSCs in OVX mice (Fig. 7F–7H), suggesting that aspirin
treatment may provide an ideal MSC-based therapy for OVX mice by preventing MSC
deficiency which is induced by medium-term IFN-! and TNF-" overexposure.
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In summary, we have uncovered a previously unrecognized mechanism whereby elevated
levels of IFN-! and TNF-" synergistically, but not independently, cause MSC deficiency
via NF#B–mediated activation of SMAD7 in OVX mice, whereas long-term elevated levels
of IFN-! and TNF-" synergistically result in increased tendency toward MSC malignant
transformation through NF#B–mediated upregulation of the oncogenes c-Fos and c-Myc
(Supporting Information Fig. S11). Thus, as a therapeutic regimen, systemic administration
of aspirin provides a promising approach in rescuing MSC deficiency in organ degenerative
diseases, as well as preventing MSC tumorigenesis through reducing the levels of IFN-! and
TNF-".

DISCUSSION
It has been well documented that estrogen deficiency increases levels of IFN-! and TNF-"
thereby enhancing osteoclast activity in OVX mice [3–5]. However, it has been unclear
whether elevated levels of IFN-! and TNF-" contribute to the impairment of MSCs/
osteoblasts in OVX mice or osteoporotic humans [2, 10–13]. In this study, we found that
elevated levels of IFN-! and TNF-" synergistically induce osteogenic deficiency of MSCs
through NF#B/SMAD7, whereas long-term overexposure of IFN-! and TNF-" can induce
malignant transformation of MSCs.
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TNF-" is widely accepted as a proinflammatory cytokine, serving as a prerequisite in
several models of inflammatory and autoimmune diseases. However, IFN-! is believed to
possess both proinflammatory and anti-inflammatory properties, such as inhibiting IL-1
production, and, as such, it also plays a complex role in inflammation and autoimmune
diseases [42]. The respective effects of IFN-! and TNF-" in osteogenic differentiation of
MSCs have remained controversial [28, 43–47]. The discrepancies in the effects of IFN-!
and TNF-" among these studies may be attributed to the different doses of IFN-! and TNF", treatment, variations between the microenvironments and MSC growth status.
Nonetheless, IFN-! and TNF-" do not present independently in vivo; instead, they are
simultaneously secreted by activated Th1 and other immune cells and cooperatively create
proinflammatory microenvironments. Indeed, our data demonstrated that high levels of IFN! and TNF-" synergistically play a crucial role in causing MSC deficiency in OVX mice,
thereby causing the phenotypes of osteoporotic bone or derma atrophy in OVX mice.
Blockage of either IFN-! or TNF-" with their neutralizing antibodies in vivo is sufficient to
effectively rescue MSC deficiency. Furthermore, OVX is not able to induce MSC deficiency
in IFN-! and TNF-" KO mice respectively, suggesting that IFN-! and TNF-" act together,
not independently, to induce MSC deficiency in the OVX model. Since OVX can induce
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elevation of multiple inflammatory cytokines, it is possible that other cytokines, with the
exception of IFN-! and TNF-", may contribute to OVX-induced MSC impairment in OVX
mice. For example, interleukin-1 (IL-1) has been proved to enhance osteoclastogenesis in
OVX mice [48]. Thus, further study is required to clarify the role of other inflammatory
cytokines in OVX-induced osteoporosis. In this study, we demonstrate that IFN-! and TNF" play a crucial role in synergistically inducing MSC deficiency in OVX mice. Given the
fact that MSCs derived from derma and subcutaneous fat have different changes in
population doublings and osteogenic differentiation after OVX, the effects of IFN-! and
TNF-" in inducing MSC deficiency may be associated with tissue levels of IFN-! and TNF".
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It has been demonstrated that IFN-! and TNF-" may activate STAT-1 and NF#B pathways,
thereby interacting with their common basal transcription complexes to affect coactivator
recruitment in fibroblasts and asthmatic airway smooth muscle cells, respectively [49, 50].
IFN-! and TNF-" have also been reported to synergistically activate STAT-1/IFN
regulatory factor-1 and c-Jun NH2-terminal kinase (JNK) pathways to induce apoptosis of
pancreatic beta-cells in autoimmune diabetes [51, 52]. However, it is unclear how
overexposure of stem cells to the synergistically activity of IFN-! and TNF-" affects their
behavior during the course of degenerative diseases. In this study, we demonstrated that
IFN-! binds its receptor IFNGR1 to strongly enhance TNF-"/TNFR1-upregulated NF#B,
which, in turn, mediates inhibitory SMAD7 to downregulate the osteogenic master gene
Runx2 [53] and, hence, induce osteogenic deficiency in MSCs, both in vivo and in vitro. In
our previous studies, we proved that TNF-" converts the signaling of the IFN-!–activated,
nonapoptotic form of FAS in BMMSCs to a caspases-associated proapoptotic cascade,
resulting in the apoptosis of implanted BMMSCs [28]. Such difference in the final fates of
MSCs may be caused by high levels of IFN-! and TNF-" produced by more intensive local
infiltration of Th1 cells in tissue-engineered transplants when compared with those in a
degenerative disease model, such as OVX mice. The synergistic dose-dependent effects of
IFN-! and TNF-" indicate that pro-inflammatory microenvironments in degenerative
diseases and tissue engineering are hierarchical and complex for the alteration of MSCs.
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It has been suggested that TNF-" may drive malignant tumor progression and that NF-#B
signaling may be involved in tumor development [16, 54, 55]. However, it has been
unknown whether long-term overexposure of synergistically active IFN-! and TNF-" could
cause malignant transformation of MSCs. In this study, we extended the period of IFN-!
and TNF-" overexposure and found that the ultimate effect was upregulation of the
oncogenes c-Fos and c-Myc via NF-#B signaling, thereby causing increased tendency
toward MSC tumorigenesis, both in vitro and in vivo. Furthermore, carcinogen-treated OVX
IFN-! and TNF-" knockout mice showed a markedly lower incidence of sarcoma with
delayed sarcoma occurrence, indicating that IFN-! and TNF-" must work together, not
independently, to upregulate NF-#B-mediated oncogenes c-Fos and c-Myc. Thus, it is
plausible that both organ degenerative diseases and malignant tumor might be “stem cell
diseases”, in which IFN-! and TNF-" overexposure plays a dynamic role in inducing MSC
deficiency and MSC tumorigenesis through activation of NF#B-mediated SMAD7 and the
oncogenes c-Fos/c-Myc, respectively.
As a widely used anti-inflammatory drug, aspirin is able to inhibit osteoclastogenesis and
improve osteogenesis in OVX mice by inhibiting cyclooxygenases and upregulating
telomerase in BMMSCs [10, 56]. Since aspirin can block Th1 cell development [57] and
reduce TNF-"– and IFN-!–producing cells in implanted tissue-engineered bones [28], we
hypothesized that aspirin should be able to block TNF-" and IFN-! in OVX mice and
therefore rescue MSC deficiency and MSC tumorigenesis. Indeed, we demonstrated that
systemic administration of aspirin was able to decrease concentrations of TNF-" and IFN-!,
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both in serum and bone marrow, and prevent MSC deficiency and carcinogen-induced MSC
tumorigenesis in OVX mice. Therefore, aspirin may be a promising drug to treat estrogen
deficiency-induced MSC deficiency and reduce the risk of tumor occurrence. However,
cautious evaluation is needed before these findings in mice would accurately translate to
humans. On one hand, although aspirin was shown to be associated with higher BMD at
multiple skeletal sites in a cohort study of men and women [58], Bauer et al. [59] only
observed a modest beneficial effect on BMD in another cohort study of postmenopausal
women. On the other hand, although daily aspirin has been proved to decrease the risk of
adenocarcinoma metastasis in a randomized controlled trial [17], a recent study indicated
that regular administration of aspirin and other nonsteroidal anti-inflammatory drugs was
associated with a slightly higher incidence of follicular lymphoma incidence [60]. Thus, the
daily use of aspirin or nonsteroidal anti-inflammatory drugs and the risk of cancer in human
should be investigated carefully using large cohorts of patients. Also, large cohort studies
are required to determine the effects of aspirin in treating post-menopausal osteoporosis and
other organ degenerative diseases. Moreover, it is known that MSCs possess such
immunomodulatory properties as immunosuppression [61]. Therefore, it will be interesting
to examine whether host MSCs show any immunosuppressive effects, such as inhibition of
activated T cells and NK cells, thereby serving as a self-protecting mechanism against
potential autoimmune reactions by the host immune system.
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CONCLUSION
In summary, this study demonstrated that TNF-" and IFN-!, as two important
representative inflammatory factors, play a crucial role in synergistically inducing MSC
deficiency and eventual MSC tumorigenesis via the NF#B pathway in OVX–induced
osteoporotic mice. Anti-inflammatory treatment, such as aspirin administration, prevents
MSC deficiency and malignant transformation in OVX mice.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Elevated levels of IFN-! and TNF-" are associated with MSC deficiency in OVX mice

(A) ELISA analysis showed that IFN-! and TNF-" levels were elevated in serum, bone
marrow and derma, but not in fat, in OVX mice. (B) OVX-derived bone marrow MSCs
(BMMSCs) showed markedly decreased population doublings, as compared with shamderived BMMSCs. (C) Alizarin red staining showed that OVX-derived BMMSCs had a
lower capacity to form mineralized nodules than those derived from sham mice when
cultured under osteogenic inductive conditions. (D) OCT-4 immunostaining showed that
derma, but not fat, from OVX mice harbored markedly less MSCs when compared with
sham-operated mice. (E) Trichrome staining showed that derma from OVX mice contained
less collagen deposition than sham-operated mice. (F) OVX-derived dermal MSCs
(DMSCs), but not fat MSCs (FMSCs), showed markedly decreased population doublings as
compared with sham-derived DMSCs. (G) Alizarin red staining showed that OVX-derived
DMSCs, but not FMSCs, had a lower capacity to form mineralized nodules than those from
sham mice. Error bars represent mean ± SEM, n = 8 animals per group. *, P < 0.05. Scale
bars, 100 %m.
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Figure 2. Depletion of either IFN-! or TNF-" is sufficient to rescue MSC deficiency in OVX
mice

(A) H&E staining showed that either IFN-! or TNF-" neutralizing antibody administration
markedly inhibited bone loss in OVX mice, respectively. (B) Either IFN-! or TNF-"
neutralizing antibody in vivo treatment markedly improved population doublings and
mineralized nodule formation in OVX-derived BMMSCs. (C) H&E staining showed that
either IFN-! or TNF-" neutralizing antibody was able to prevent OVX-induced derma
atrophy. (D) Either IFN-! or TNF-" neutralizing antibody in vivo treatment markedly
improved population doublings and differentiation of OVX-derived DMSCs. (E, F) BMD in
femurs was not significantly changed at 1 month post OVX when compared with BMD of
sham-operated femurs in IFN-! and TNF-" knockout mice, respectively. Population
doublings and osteogenic differentiation of BMMSCs and DMSCs were not significantly
altered in OVX IFN-! and TNF-" knockout mice. Error bars represent mean ± SEM, n = 5
animals per group. *, P < 0.05. Scale bars, 100 %m.
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Figure 3. IFN-! and TNF-" synergistically induce MSC deficiency in nude mice
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(A–D) Infusion of IFN-! and TNF-" in combination, but not separately, caused a dramatic
reduced population doublings and osteogenic differentiation of BMMSCs and DMSCs, as
indicated by Alizarin red staining. (E) Histological quantification demonstrated that only the
group infused with both IFN-! and TNF-" showed significant decrease in trabecular bone
thickness. (F–G) Trichrome staining showed that IFN-!/TNF-" treatment group had poor
collagen deposition and derma atrophy. Error bars represent mean ± SEM, n = 5 animals per
group. *, P < 0.05. Scale bars, 100 %m.
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Figure 4. IFN-! and TNF-" synergistically activate NF#B/SMAD7 pathway, resulting in
BMMSC deficiency
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(A) Western blot showed upregulation of p-NF#Bp65, p-I#B, SMAD7, but downregulation
of p-SMAD1, RUNX2 and ALP in OVX-derived BMMSCs. (B) When BMMSCs were
treated with IFN-! and TNF-", combination of IFN-! (50 ng/ml) and TNF-" (5 ng/ml)
treatment caused significant upregulation of NF#Bp65 and p-I#B, as assessed by Western
blot analysis. (C) Alizarin red staining showed that IFN-! and TNF-" in combination, but
not independently, caused a markedly reduced mineralized nodule formation in BMMSCs.
(D) Western blot showed that IFN-! and TNF-" treatment in combination was able to
dramatically upregulate IFNGR" and TNFR1, but not TNFR2, under osteogenic induction.
IFN-!, either alone or in combination with TNF-", was able to markedly upregulate pSTAT-1. (E) Toluidine blue staining showed that neither IFN-! nor TNF-" treatment
affected MSC survival. (F) Western blot showed that TNF-"–/IFN-! –induced NF#B
activation upregulated SMAD7, but downregulated the osteogenic markers p-SMAD1,
RUNX2 and ALP. (G–H) With knockdown of NF#B by IKK" siRNA assay, TNF-"–/IFN!–induced upregulation of SMAD7 and downregulation of p-SMAD1, RUNX2 and ALP
were abolished, leading to the rescue of TNF-"–/IFN-!–induced reduction of mineralized
nodule formation in BMMSCs. (I, J) Systemic administration of NF#B inhibitor Bay
11-7082 in OVX mice was able to rescue mineralized nodule formation capacity of
BMMSCs, by downregulating SMAD7 and upregulating p-SMAD1, RUNX2, and ALP in
BMMSCs, as shown by Western blot analysis. (K, L) Western blot showed that OVX failed
to induce upregulation of NF#Bp65 and p-I#B in IFN-! or TNF-" null BMMSCs,
respectively. (M) Either IFN-! or TNF-" neutralizing antibody in vivo treatment was able
to downregulate NF#Bp65 and p-I#B in BMMSCs. Error bars represent mean ± SEM, and
all experiments were performed in triplicate. n = 5 animals per group. *, P < 0.05.
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Figure 5. Long-term exposure of MSCs to IFN-! and TNF-" synergistically contributes to
increased susceptibility to tumor occurrence in OVX mice

(A) OVX mice at age 1 year showed a markedly increased tumor incidence when compared
with age-matched sham mice. (B) ELISA showed that both IFN-! and TNF-" concentration
in serum remained markedly higher in OVX mice when compared with sham mice. (C)
When MCA was injected to tibias, OVX mice showed a markedly higher sarcoma incidence
with earlier sarcoma occurrence in tibias when compared with sham mice. (D) H&E staining
showed the production of osteoid (O) by atypical tumor cells (A) with high mitotic activity
(M) and abundant neovascularization (V) in the tumors of MCA-treated OVX mice.
Trichrome staining showed osteogenic differentiation (O) of osteosarcoma-like tumor cells
in MCA-treated OVX mice. (E) Immunostaining showed that CD73 was highly overlapped
with VIM or PCNA in the tumors of MCA-treated OVX mice. (F) MCA-treated OVX mice
showed a markedly lower sarcoma incidence with delayed sarcoma occurrence in IFN-! or
TNF-" knockout mice, respectively, when compared with the sham-operated mice. Error
bars represent mean ± SEM, n = 10–18 animals per group. *, P < 0.05. Scale bars, 50 %m.
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Figure 6. Long-term IFN-!/TNF-" exposure increases susceptibility to MSC malignant
transformation via NF#B-induced oncogenes

(A) In an in vitro spontaneous malignant transformation assay, long-term treatment of IFN!/TNF-" showed a markedly quicker increase in population doublings after passage 10
(arrow), whereas NF#B inhibitor was able to delay such increase. (B) Giemsa staining
showed that IFN-!/TNF-"-treated BMMSCs presented markedly smaller morphology with
frequent abnormal mitosis. Upon s.c. inoculation and tail vein infusion, sarcoma-like tumors
grow in situ and settled in lungs with tumorigenesis in immunocompromised mice (red
arrows), as assessed by H&E staining. In contract, NF#B inhibitor-treated and control
BMMSCs maintained large cell morphology, with no tumor generation upon s.c. inoculation
or infusion into immunocompromised mice. Scale bars, 50 %m. (C) Western blot showed
that expression of c-FOS and c-MYC was markedly elevated in long-term IFN-!/TNF-"treated BMMSCs when compared with control BMMSCs. Knockdown of NF#B by IKK"
siRNA treatment was able to abolish elevated expression of c-FOS and c-MYC. (D) Realtime PCR showed that c-Fos and c-Myc were markedly elevated in BMMSCs derived from
aging OVX mice when compared with sham mice. (E) Western blot showed that c-FOS and
c-MYC expression was enhanced, along with NF#B activation, in BMMSCs derived from
aging OVX mice. Error bars represent mean ± SEM, n = 4 animals per group, and all
experiments were performed in triplicate. *, P < 0.05.
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Figure 7. Aspirin blocks OVX-induced tumorigenesis and MSC deficiency by inhibiting IFN-!
and TNF-"

(A) Systemic aspirin treatment resulted in a markedly decreased and delayed osteosarcoma
occurrence in MCA-treated OVX mice. (B) ELISA showed that aspirin treatment
dramatically reduced the levels of IFN-! and TNF-" in both serum and bone marrow. (C)
Western blot showed markedly downregulated p-NF#Bp65 and p-I#B in BMMSCs derived
from aspirin-treated OVX mice when compared with placebo-treated OVX mice. (D)
Aspirin-treated OVX mice showed increased BMD when compared to un-treated OVX
mice. (E) ELISA showed that aspirin treatment reduced the concentrations of IFN-! and
TNF-" in serum, bone marrow and derma. (F–H) Aspirin administrated in vivo was able to
markedly improve population doublings and osteogenic differentiation of both BMMSCs
and DMSCs in OVX mice. Error bars represent mean ± SEM, n = 10–18 animals per group,
and all experiments were performed in triplicate. *, P < 0.05. Scale bars, 50 %m.
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